FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027 October Danon disease investor webinar highlighted updated longer-term RP-A501 Phase 1 findings and encouraging initial safety observations in the first three patients treated under the modified Pivotal Phase 2 protocol Dosing initiated in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy KRESLADI™ achieved commercial readiness on October

— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy — RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of once-daily ORLADEYO ® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older,

Completes SYMON-II clinical study enrollment and advances clinical validation activities. Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness. Targets FDA 510(k) submission in the first half of 2027. ACTON, MA / ACCESS Newswire / November 12, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid, near-patient testing solutions for critical care,

BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of $17.00 per share. In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,11

Opinion granted based on positive progression-free survival results from the Phase 3 LITESPARK-011 trial If approved, this regimen will be the first and only approved combination of a HIF-2α inhibitor and a multi-targeted VEGFR-TKI in the European Union RAHWAY, N.J.--(BUSINESS WIRE)-- $MRK #MRK --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion

SAN DIEGO--(BUSINESS WIRE)-- $TVTX --Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were g

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will present at the Jefferies Global Healthcare Conference in London on Thursday, November 19, 2026, at 8:30 a.m. GMT / 3:30 a.m. EST. A live webcast of the presentation will be available on the “Events” page of the “Investors” section of the Company’s w

Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026 Phase 2 data in bronchiolitis obliterans syndrome (BOS) post lung transplant anticipated in the first quarter of 2027 Cash, cash equivalents and investments of $105.2 million as of September 30, 2026 expected to fund operations through the end of 2028 with multiple Phase 2 clinical data readouts NEW HAVEN, Conn., Nov. 13, 202

Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025 Fortress repaid its credit facility in full in September 2026 A subsidiary of Fortress entered into a license agreement for FB-607, which is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety and efficacy in patients with irritable bowel syndrome with diarrhea Partnered programs continue to advance, with Crys

Building on Nanox.AI's existing deployment in Athens, the agreement supports commercial expansion in Greece through Medworks ' established market presence. PETACH TIKVA, Israel, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that it has entered into a non-exclusive distribution agreement with Medworks LTD (“Medworks”) to support the commercial expansion of Nanox.AI’s HealthOST